Investigation of correlation between the two indexes used to determine the progression of pathological conditions in liver disease (the FIB4 index [an index of progression of liver fibrosis] and the liver fibrosis stage as assessed by FibroScan [a liver fibrosis staging index]) - Investigation of correlation between the two indexes used to determine the progression of pathological conditions in liver disease (the FIB4 index [an index of progression of liver fibrosis] and the liver fibrosis stage as assessed by FibroScan [a liver fibrosis staging index])

Medical Corporation Chiseikai Tokyo Center Clinic0 个研究点目标入组 3,150 人开始时间: 2021年11月10日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Those with a history or suspected history of alcoholic liver disease. Significant alcohol intake within 2 years prior to informed consent (mean intake above 210 g/week for men and above 140 g/week for women) for more than 3 consecutive months. 2) Medical history of other chronic liver diseases (viral hepatitis, autoimmune liver disease, primary sclerosing cholangitis, Wilson's disease, hemochromatosis, A1AT deficiency, treatment history of liver transplantation, etc.) 3) Suspected, diagnosed, or history of hepatocellular carcinoma or active, suspected, or history of malignant tumor within 5 years before screening ; however, patients with appropriately treated basal cell carcinoma of the skin or cervical carcinoma in situ do not need to be excluded. 4) Diagnosis of serious or unstable disease of the liver (other than NASH), kidney, digestive organs, respiratory organs, cardiovascular system (including ischemic heart disease) or endocrine, neurological, mental, immune, or blood disorders or other medical conditions that may affect the investigations in this study according to the clinical judgment of the principal investigator. 5) Those who are pregnant or who use a pacemaker.

发起方

Medical Corporation Chiseikai Tokyo Center Clinic